Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Status:
Completed
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It
has ani-fibrotic properties. Previous studies have shown that relaxin is safe at
concentrations upto 60 times higher than achieved in pregnancy. Study is designed to see if
skin improvement and improvement in functional ability can be achieved.
Phase:
Phase 3
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborators:
Boston University Georgetown University Johns Hopkins University Medical College of Wisconsin Medical University of South Carolina Stanford University UConn Health University of California, Los Angeles University of California, San Diego University of Chicago University of Colorado, Denver University of Pittsburgh Wayne State University